Engage Therapeutics

7 articles about Engage Therapeutics

• UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

  6/5/2020

  Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure

• Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for Seizure Cessation Meets Primary Endpoint

  3/12/2020

  Engage Therapeutics, Inc. announced that its Phase 2b StATES study of Staccato® alprazolam met its primary endpoint which was proportion of responders achieving cessation of seizure activity within two minutes of treatment administration and no recurrence within two hours.

• Engage Therapeutics Announces Two Poster Presentations at the American Epilepsy Society’s Annual Meeting

  12/4/2019

  Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode in patients who experience breakthrough seizures while on an antiepileptic drug, today announced two poster presentations at the American Epilepsy Society’s Annual Meeting (AES 2019), which is being held Dec. 6-10,

• Engage Therapeutics to Present at the Stifel 2019 Healthcare Conference

  11/12/2019

  Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode in patients who experience breakthrough seizures while on an antiepileptic drug, will participate in the Stifel 2019 Healthcare Conference in New York City.

• Engage Therapeutics Announces Data from Phase 2a, Proof-of-concept Study of Staccato Alprazolam to Suppress Seizures in Patients with Epilepsy Published in Epilepsia

  7/9/2019

  Engage Therapeutics, Inc. announced that data from a phase 2a study of Staccato® alprazolam to suppress seizures in patients with epilepsy were published in the peer-review journal Epilepsia.

• Atchison Hospital Goes LIVE with MEDITECH Expanse EHR

  4/24/2019

  The new Expanse EHR consolidates patient records across all points of care and provides the hospital with a technology platform that will allow for continued innovation.

• Engage Therapeutics Lands $23 Million for Epilepsy Drug-Device Therapy

  9/27/2017